ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Asthenia in cancer patients receiving immune checkpoint Inhibitors (ICIs): the MOUSEION-11 systematic review and meta-analysis.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe MOUSEION-11 systematic review and meta-analysis aimed to assess the rates of asthenia in patients receiving immune checkpoint inhibitors (ICIs) compared with those who received non-immunotherapeutic regimens or placebo ones.
methodsThe MOUSEION-11 was recorded with PROSPERO n. CRD420250654013 and carried out following the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA).
resultsFor any-grade asthenia, 39 studies were included. The pooled prevalence was 15.6% (95% CI: [10.4%; 22.7%]) under a random-effects model, with significant very high heterogeneity (P < 0.001; tau
conclusionDespite the incidence of asthenia in patients receiving ICI, no treatments have been tested to palliate ICIs-induced asthenia.
Indexed as
Identifiers
42322559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.